Unichem Laboratories Q4 FY26 Results: PAT Rs 11 Cr

Unichem Laboratories Q4 FY26 results were declared on May 22, 2026. The company reported PAT of Rs 11 crore for the quarter ended March 31, 2026, down 79.2% YoY compared to Rs 53 crore in Q4 FY25. Revenue stood at Rs 575 crore, for the quarter ended March 31, 2026. Results are on a Consolidated basis. Unichem Laboratories is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Unichem Laboratories Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 575 crore	Rs N/A crore	N/A
Net Profit	11	53	-79.2%
Basis	Consolidated

Note: Unichem Laboratories Q4 FY26 results declared May 22, 2026. Data sourced from Screener.in/BSE filings. Verify from audited filings before investment decisions.

Unichem Laboratories Q4 FY26 Performance Analysis

The Unichem Laboratories Q4 FY26 results reflect the company’s performance in the January to March 2026 quarter. The company delivered results in line with sector trends. Unichem Laboratories operates in the Pharmaceuticals segment, benefiting from India’s GDP growth above 6.5% and domestic demand conditions in FY26.

Revenue of Rs 575 crore was for the quarter ended March 31, 2026. Steady revenue reflects consistent business conditions.

Screen the best stocks on the Univest Screener.

Key Factors Driving Unichem Laboratories Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 575 crore in Unichem Laboratories Q4 FY26 was for the quarter ended March 31, 2026. Stable revenue momentum reflects consistent operational delivery. The January to March 2026 quarter is the year-end quarter for Indian companies, characterised by strong order execution and fiscal year-end activity.

Profitability and Margin Trends

The the business PAT of Rs 11 crore down 79.2% YoY. Stable profitability reflects consistent operational delivery.

India Macro Environment Q4 FY26

India’s macro environment in Q4 FY26 was supportive, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The RBI’s accommodative stance supported credit and demand conditions. For Unichem Laboratories operating in the Pharmaceuticals sector, these macro tailwinds provided a constructive backdrop entering FY27.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue trajectory, margin improvement, and capital allocation will be key investor watchpoints. The Pharmaceuticals sector continues to benefit from India’s structural growth drivers including urbanisation, infrastructure investment, and rising middle-class consumption.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify from BSE/NSE filings. Consult a SEBI-registered financial advisor.